

A Synthesis Approach of Mouse Studies to Identify Genes and Proteins in Arterial Thrombosis and Bleeding

Constance C. F. M. J. Baaten^{1,2*}, Stuart Meacham^{3*}, Susanne M. de Witt^{1*}, Marion A. H. Feijge¹, David J. Adams⁴, Jan-Willem N. Akkerman⁵, Judith M. E. M. Cosemans¹, Luigi Grassi³, Steve Jupe⁶, Myrto Kostadima³, Nadine J. A. Mattheij¹, Martin H. Prins⁷, Ramiro Ramirez-Solis⁴, Oliver Soehnlein^{8,9,10}, Frauke Swieringa¹, Christian Weber^{8,9}, Jacqueline K. White⁴, Willem H. Ouwehand^{3,4*}, Johan W. M. Heemskerk^{1*}

¹Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands, ²Institute for Molecular Cardiovascular Research (IMCAR), University Hospital Aachen, RWTH Aachen University, Aachen, Germany, ³Department of Haematology, University of Cambridge and NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, United Kingdom, ⁴Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton Cambridge, United Kingdom, ⁵Laboratory of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands. ⁶EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom, ⁷Department of Clinical Epidemiology, Maastricht University Medical Centre, Maastricht, The Netherlands, ⁸Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany, ⁹DZHK, partner site Munich Heart Alliance, Munich, Germany, ¹⁰Department of Pathology, AMC, Amsterdam, The Netherlands. *Equal contribution.

Corresponding authors:

Johan W. M. Heemskerk, Department of Biochemistry, CARIM, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Phone: +31-43-3881671; Fax: +31-43-3884159; E-mail: jwm.heemskerk@maastrichtuniversity.nl

Willem H. Ouwehand, Department of Haematology, University of Cambridge & Wellcome Sanger Institute and NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, CB2 0PT United Kingdom. Phone: +44 (0)1223 58 8037/8018; E-mail: who1000@cam.ac.uk

Keywords: arterial thrombosis, bleeding, coagulation, platelets, thrombus.

Word count: abstract 250; main text 4593

6 figures; 2 supplemental files

33 references

Key points

- A synthesis method was developed comparing the roles of 431 mouse genes in arterial thrombosis with or without affecting hemostasis.
- A network of protein interactions in thrombosis/hemostasis revealed high similarity in mouse and man, and identified candidate proteins.

Abstract

Antithrombotic therapies reduce cardiovascular diseases by preventing arterial thrombosis and thromboembolism, but at expense of increased bleeding risks. Arterial thrombosis studies using genetically modified mice have been invaluable for identification of new molecular targets. Because of low sample sizes and heterogeneity in approaches or methodologies, a formal meta-analysis to compare studies of mice with single gene defects encountered major limitations. To overcome these, we developed a novel synthesis approach to quantitatively scale 1514 published studies of arterial thrombus formation (*in vivo* and *in vitro*), thromboembolism and tail bleeding of genetically modified mice. Using a newly defined consistency parameter (CP), indicating the strength of published data, comparisons were made of 431 mouse genes, of which 17 consistently contributed to thrombus formation without affecting hemostasis. Ranking analysis indicated high correlations between collagen-dependent thrombosis models *in vivo* (FeCl₃ injury or ligation/compression) and *in vitro*. Integration of scores and CP values resulted in a network of protein interactions in thrombosis and hemostasis (PITH), which was combined with databases of genetically linked human bleeding and thrombotic disorders. The network contained 2,946 nodes linked to modifying genes of thrombus formation, mostly with expression in megakaryocytes. Reactome pathway analysis and network characteristics revealed multiple novel genes with potential contribution to thrombosis/hemostasis. Studies with additional knockout mice revealed that 4/8 (*ApoE*, *Fpr2*, *Ifnar1*, *Vps13a*) new genes were modifying in thrombus formation. The PITH network further: (i) revealed a high similarity of murine and human hemostatic and thrombotic processes, and (ii) identified multiple new candidate proteins regulating these processes.

Introduction

Cardiovascular disease, due to vaso-occlusive arterial thrombosis or thromboembolism, is a leading cause of disability and death worldwide.¹ Extensive research over the last decades has provided drugs that result in a significant, albeit incomplete reduction of disease-related mortality and morbidity. Apart from pharmacological agents lowering plasma lipids and blood pressure, antiplatelet and anticoagulant agents are effective in the secondary prevention of thrombotic complications.²⁻⁴ Yet, current treatment regimens are still partly effective, while causing bleeding complications in at least 2% of the patients. This has led to a continued search for better targeted antithrombotic medication with minimal bleeding.

In the past two decades, hundreds of mouse studies have been performed to evaluate consequences of genetic modification or pharmacological intervention in experimental models of arterial thrombosis or thrombo-embolism.^{3, 5, 6} The connecting aim of such studies is to disclose particular platelet, coagulation or vascular proteins that regulate thrombosis and/or hemostasis. However, these studies typically use low numbers of mice (typically 6-12), and assess arterial thrombus formation or thrombo-embolism *in vivo* or *in vitro*, using different methodologies and measurement outcomes. This variation has hampered a systematic comparison of the use of thrombosis models across genes. The few published reviews provide qualitative rather than quantitative descriptions of the effects of genetic modification on thrombus formation or tail bleeding.^{3, 5, 7, 8} On the other hand, many of the published effects of murine gene deletion faithfully phenocopy the known effects of Mendelian inherited bleeding and platelet disorders in man, thus proving their relevance for disease.^{9, 10} This prompted us to develop new means for quantitative comparison of published studies regarding

altered thrombosis and bleeding tendencies as a consequence of genetic modification in mice.

Published reports on murine arterial thrombosis have in common an experimental approach, in which vascular damage is induced by activation or injury of the endothelium to cause exposure of the collagen-containing subendothelial matrix.¹⁰ Nevertheless, *in vivo* methods differ regarding (i) the type of injured vascular bed, (ii) the type and strength of the injury, (iii) equipment and detection methods, and (iv) outcome parameters. Hence, for systematic comparison of multiple studies, an analytical tool needs to be developed that is scaled and takes into account these variables. The same applies to *in vitro* tests, where microfluidics devices for whole blood perfusion are employed as proxy measurements of arterial thrombus formation.¹¹⁻¹³ Such *in vitro* tests are relevant from a translational point of view, since the same devices can be used to detect deficiencies in human platelet and coagulation activity and to determine the efficacy of antithrombotic medication.¹³⁻¹⁷

In the present paper, we developed and validated a scaling procedure as a synthesis approach to compare published studies on effects of genetic modification on arterial thrombus formation, thromboembolism and/or tail bleeding. This synthesis gave an unprecedented insight into the relative roles of multiple mouse genes, in majority regulating platelet, coagulation or vascular functions.

Methods

For a more extended description of the methods, see supplementary file.

A PubMed search over the years 1980-2018 was performed to identify papers on mouse studies in relation to arterial thrombus formation, thromboembolism and tail

bleeding (Suppl. Table 1). From these papers information on genetics, experimental models and outcome parameters was gathered (Data File 1).

As an alternative synthesis approach, 1514 studies* were grouped per experimental method, vascular bed of injury, and outcome thrombus parameter (mass-dependent, time-dependent and stability measurements, bleeding times) and then normalized on a 3-point or 5-point scale. Mean scores per group, parameter type and gene were compared using the non-parametric Kendall's Tau-c test. To assess consistency and strength of scaled studies per gene, a consistency parameter (CP) was defined as $1 - \log(P)$, with P values from a one-sample t-test.

Animals came from breeding programs of the Wellcome Sanger Institute Mouse Genetics Programme (Cambridge, United Kingdom) and the Institute for Cardiovascular Prevention in Munich (Germany). Animal experiments were approved by the local Animal Experimental Committees.

Results

Data collection of mouse studies reporting on genetic modification or pharmacological intervention affecting arterial thrombosis, thromboembolism or tail bleeding

A PubMed search was performed across scientific publications over the period 1980-2018, resulting in 610 publications containing quantified data (with statistics) on effects of genetic or pharmacological perturbation on arterial thrombus formation, thromboembolism or tail bleeding in mice. The majority of the papers concerned mice

* 1431 studies published before January 2018

with a single genetic deficiency, resulting in altered platelet, coagulant or vascular function. The published studies were classified (Figure 1) as *in vivo* arterial thrombosis (class I), *in vivo* thromboembolism (class II), *in vitro* arterial thrombus formation (class III), or tail bleeding (class IV). Manuscripts as well as published reviews were screened for further primary sources, thereby, including another 32 publications. Individual studies were defined as reporting on effects of genetic modification per vascular bed or way of injury, resulting in a database of 1514 studies* (Data File 1).

Conventional meta-analysis and limitations

As a first approach to quantitatively compare outcomes of thrombosis studies per mouse gene, a conventional meta-analysis was performed for the most studied mouse strains. Given the diversity between studies (thrombosis model, detection method, and parameter measured), a standard random effects model was considered most appropriate. To achieve a certain degree of inter-study consistency, only studies were included where FeCl₃ was used to induce thrombosis in either the carotid, mesenteric or femoral arteries/arterioles, and where time-dependent parameters were reported (see Suppl. Methods). For six genes, data could thus be obtained from a small number (*n*) of studies: *Cd36* (4), *Clec1b* (3), *F12* (4), *Fcer1g* (2), *Gp6* (6) and *Vwf* (3) (Figure 2). Meta-analysis per gene, using the Cochrane group RevMan 5.1 program, pointed to a significantly prolonged thrombus formation in mice with genetic deficiency in *F12*, *Gp6* or *Vwf* ($P=0.0008-0.003$), while there was a tendency to prolongation in mice lacking *Cd36*, *Clec1b* or *Fcer1g* ($P=0.05-0.08$). A limitation of this meta-analysis approach however is the large heterogeneity index for all genes ($I^2=73-88\%$), even when statistical significance is reached. We reasoned that this high heterogeneity is

unavoidable, since animal experiments are *de facto* quite small in size, and furthermore vary in experimental conditions and outcome parameters. We further noticed that a heterogeneity test is low in power, when sample size is small and few trials are included.¹⁸ This prompted us to search for a better method to compare and normalize effects of genetic knock-out in a larger set of published studies.

Study scaling and subdividing of parameters of arterial thrombus formation, thromboembolism and tail bleeding

As an alternative approach to compare and normalize published effects of gene inactivation on arterial thrombus formation and bleeding, we searched for a synthesis procedure that is condition independent. A simple method is to scale the published effect of genetic perturbation (*e.g.* quantifiable difference between wild type and genetically modified mice) on a 3-point or 5-point scale (Figure 1). Herein, the 3-point scale discriminates between a decrease and increase of the parameter determining the thrombotic process; while the 5-point scale further distinguishes between a moderate/strong decrease and increase. For convenience, we refer to the results of this scaling as 'scores.'

For the database of 1431 studies (*i.e.*, those published before January 2018) we performed a consistency analysis to determine if scores per class were comparable depending on the type of vascular bed, the injury trigger, and the parameter of measurement. The original papers were mined for quantitative data on arterial thrombosis, thromboembolism or tail bleeding (Suppl. methods). Weighing was not performed, because of the similar sample size of studies and the lack of calibration options.

For studies on thrombus formation *in vivo* (class I) and *in vitro* (class III), we separated the published data into time-, mass- or stability-dependent parameters. To accommodate different measurement outcomes, we further divided the mass-dependent parameters in three sub-parameters, *i.e.* platelet adhesion, vessel occlusion and thrombus size (Suppl. Table 2).

Comparative analysis *within* studies of class I and class III, applied to the whole database, showed significant correlations between the three mass-dependent sub-parameters (class I: *bi-biii*, class III: *gi-giii*), at 3-point and mostly also at 5-point scale, with Kendall's $\tau \geq 0.54$ ($P < 0.050$) (Suppl. Table 3A-B). This allowed combination of the sub-scores into one mass-dependent score per study. Subsequently, correlation analysis pointed to a high similarity of time-, mass- and stability-dependent parameters, again *within* individual studies of the whole database (Suppl. Table 3C-D). In class I, these parameters correlated with $P < 0.001$, except when comparing time and stability parameters at a 5-point scale ($P = 0.226$). In class III, with lower sample size, the time- and mass-dependent parameters correlated with $P = 0.046$ (3-point) or 0.072 (5-point); thrombus stability was hardly measured in class III. Together, the overall high consistency of scaling of time-, mass- and stability-dependent parameters made it possible to combine these per study into one mean synthesis score (3- and 5-point scale), as a calibrated outcome of the gene modifying effect in that particular vascular bed and injury type. Studies of arterial thromboembolism (class II) and tail bleeding times (class IV) were also scaled at 3- and 5-point.

Comparison of scaling for different experimental models of thrombus formation and thromboembolism

In 205 cases, mice of the same breeding were used in one paper for class I/II *in vivo* studies as well as for class III *in vitro* studies (Data File 1, same rows). This allowed us to directly compare the scores of such studies (Suppl. Table 4). For the database as a whole, this resulted in significant correlations for the 3- and 5-point scaling of class I ($P < 0.001$, $n = 151$) and class II ($P = 0.006$ and 0.268 , $n = 14$) studies, when compared to class III studies in the same paper. Hence, overall, the scaling of the *in vitro* thrombus formation appears to be in good agreement with that of *in vivo* arterial thrombosis.

Next, we compared per gene the results obtained for different vascular beds or injury types. Grouping the studies according to these variables (Figure 1 and Suppl. Table 2) revealed that, for class I studies, the mostly used vascular beds were carotid artery > mesentery > cremaster > aorta; while the most popular injury methods were FeCl_3 > laser > photochemical > vessel ligation or compression > electrolytic injury (Suppl. Figure 1A). For class II, the majority of papers applied injection of collagen/epinephrine, with fewer studies using tissue factor or reporting unprovoked thrombosis (Suppl. Figure 1B). Concerning class III, mostly collagen type-I was used as thrombogenic surface (Suppl. Figure 1C). Class IV bleeding time studies were not subdivided.

For comparison of the different experimental approaches in the studies, groups in class I were combined with respect to vascular bed or injury mode. Regression analysis indicated significant correlations at 3-point and 5-point scales between the scores for carotis, mesentery and cremaster injury, when averaged per gene (Table 1). Furthermore, we found highly significant ($P < 0.001$) correlations of mean scores per

gene in class I for carotid or mesenteric injury (*i.e.*, collagen-dependent thrombosis models) with class III study scores (*i.e.*, collagen-induced thrombus formation *in vitro*). Markedly, the scaling of class I studies using cremaster injury (laser-induced, considered to be less collagen-dependent) again correlated with that of class III studies ($P < 0.001$, 3- and 5-point).

When comparing different injury modes in class I, the scaling per gene for FeCl_3 studies correlated significantly ($P \leq 0.005$, 3- and 5-point) with that for laser, photochemical or ligation/compression injuries (Table 1). Furthermore, class III scores of collagen-dependent thrombus formation were related on 3-point scale ($P = 0.006$, low $n = 14$) but not on 5-point scale ($P = 0.286$) with class II scores (thromboembolism with frequent collagen/epinephrine injection). Taken together, this analysis revealed that, overall, the scaling for classes I, II and III gave similar outcomes for effects of a certain gene deficiency, irrespective of the arterial vascular bed, injury mode, injection of collagen or *in vitro* testing.

Synthesis approach of scaled studies to compare roles of mouse genes in thrombus formation, thromboembolism and hemostasis

Considering that the 5-point scale (classes I-III) is more discriminative than the 3-point scale, we used the former for comparative analyses of the 1431 studies. As a first approach, mean scaled scores were calculated per class and gene. For 409 genes, this resulted in information on 277, 79 and 161 genes for classes I, II and III, respectively (Figure 3A). For bleeding times (class IV), information was collected for 314 genes (Figure 3A). First analysis across all genes revealed that a gene defect with a negative score for arterial thrombosis was more frequently (69%) accompanied with prolonged

bleeding than unchanged bleeding (Figure 3C).

Subsequently, for the 35 best-investigated genes ($n \geq 6$ studies across classes I-III, 65% collagen-dependent models), we evaluated the distribution of study scores in more detail (Figure 4A). We considered these scores as discretized ordinal variables with defined ranking; hence these could be treated as interval variables. This allowed calculation of 95% confidence intervals and P values, while keeping the rounded-off mean scaling per gene (Figure 4B).

A standard method to assess distribution profiles of interval variables does not exist. Based on P values obtained from normalized data (per gene, see Methods), we therefore defined a consistency parameter (CP) as $1 - \log(P)$, reflecting the uniformity and strength of the pooled study scores. Accordingly, we considered that a mean non-zero scaling with $CP > 2.30$ (corresponding to $P < 0.05$) consistently points to an anti- or prothrombotic propensity.

Following this synthesis approach it appeared that, for the best studied genes, 14 genes with mean -2 score gave a $CP > 2.30$ (in decreasing order: *Gp6*, *Fcer1g*, *F12*, *Vwf*, *Itgb3*, *Rasgrp2*, *P2ry12*, *Pik3cb*, *F8*, *Pdia3* > *Tln1*, *F2*, *F9* > *Lcp2*) (Figure 4C). Furthermore, 13 out of 17 genes with a mean -1 score had a $CP > 2.30$ (*Ptprj*, *F11*, *P2ry1* > *F2rl3* > *Orai1*, *Stim1*, *Serpine1*, *Gp1bb*, *Pld1* > *Klkb1*, *Itga2*, *Selp*, *Clec1b*). Regarding the 'prothrombotic' gene with mean score +1, *Adamts13* gave a $CP > 2.30$. Negative scores of the genes *Cd36*, *Itgb1*, *Jak2* and *Vtn* did not reach significance (Figure 4C).

The suitability of this synthesis approach prompted us to generate mean scores and CP values for all genes. In this way, it is possible to compare, across all genes, not only the overall effect size (5-point scale) but also the consistency of the reported data

of a gene defect, regarding both arterial thrombosis/thromboembolism (class I-III) and a bleeding tendency (class IV). Data File 3 provides an overview for all gene defects (or pharmacological intervention), regarding mean class scores, CP values, and a short description on altered platelet, coagulant or vascular function.

For 60 genes with $CP > 2.30$ ($P < 0.05$) and an arbitrary cutoff of $n \geq 3$ studies, the results are summarized in Table 2, separating mice with an 'antithrombotic' phenotype (negative class I-III scores) and a normal or prolonged bleeding time. For 17 genes, mostly encoding platelet receptor or signaling proteins or plasma coagulation proteins, there appears to be consistent evidence for a role in arterial thrombosis but not hemostasis. For 42 genes, encoding proteins with similar functions, the scaled data points to contribution to both thrombosis and hemostasis. In one case (deficiency in *Ceacam1/2*), a prothrombotic phenotype is accompanied with prolonged bleeding, possibly due to vascular changes.

When comparing the human orthologues of these 42 genes, it appears that mutations are often associated with bleeding events,¹⁹ especially for those corresponding to mouse genes with a -2 bleeding score (Table 2). These include *F8*, *F9*, *VWF*, *FERMT3*, *GPIBA*, *GPIBB*, *ITGB3*, *P2RY1*, *P2RY12*, *RASGRP2*, *TLN1* and *NBEAL2*. Interestingly, for several other genes (e.g., *GNA13*, *MAP3K3*, *KCNIP3*), evidence in humans of a possible role in human hemostasis is still unknown. We note here that, given the low prevalence of inherited Mendelian bleeding disorders, very little is known of a protective role in thrombosis in this group of rare patients with hemostatic insufficiencies. The mouse data would predict such a role.

Antagonists for several human orthologous proteins are already in use for patient treatment (thrombin inhibitors, *F2*; integrin $\alpha_{IIb}\beta_3$ antagonists, *ITGB3*; $P2Y_{12}$ antagonists,

P2RY12); or are studied in clinical trials (inhibitors of: factor XI and XII, *F11*, *F12*; glycoprotein VI, *GP6*; glycoprotein Ib-VWF, *GPIBA*, *VWF*; phosphoinositide 3-kinase- β , *PIK3CB*).

Reactome biological pathway analysis of (modifying) genes in arterial thrombosis and hemostasis

To translate the scoring per mouse gene/protein to human pathophysiology, we first performed an over-representation analysis using the Reactome database. This knowledgebase of biological pathways is elaborated for megakaryocytes, platelets and the coagulation system.²⁰ Pathway analysis for 405 scored genes/proteins indicated that a substantial part of the Reactome-registered hemostatic system was covered (148/ 806 proteins) (Data File 5). Well-covered pathways included platelet activation, platelet/neutrophil degranulation, and fibrin clot formation. Several unexpected pathways were also detected, e.g. linked to cancer (see Supplementary file). Additional Reactome attribute analysis, taking into account the scores per gene/protein, revealed pathways where mean scores for (modifying) proteins in class I-III were less negative than those for proteins in class IV (Data File 5). This concerned pathways of 12/15-eicosatetraenoic synthesis, matrix metalloproteinases and common fibrin clot formation, suggesting that these may play a more prominent role in hemostasis. Conversely, mean scores for proteins of Toll-like receptor pathways were more negative in class I-III than those for proteins in class IV, suggesting a more prominent role in thrombosis (Data File 5).

Network of genes and proteins implicated in arterial thrombus formation

To further exploit the dataset, a Cytoscape network was constructed with human protein orthologues of 267 genes with modifying effects on arterial thrombosis (class I-III). Using these as primary baits, a network was obtained retrieving 2,679 first order interactors (novel nodes) and 19,721 interactions (edges) (Figure 5A). The expanded network of protein interactions in thrombosis and hemostasis (PITH) was used for further exploration of new (patho)physiological pathways (Data File 6).

In order to relate to human diseases, the network was linked to several large-scale human genetic studies. As nodes, we could trace 54 genes of in total 72 genes linked to rare human Mendelian disorders of platelet or coagulation function, obtained in the NIHR BioResource Bleeding, Thrombotic and Platelet Disorders cohort,²¹ and 21 out of 68 genes from a genome wide association study (GWAS) of platelet count and volume²² (Figure 5B). The latter set encompassed 147 DNA variants in the network out of 647 variants obtained in a more recent GWAS of platelet quantitative traits (Data File 6).²³ Regarding arterial thrombosis, 11 genes were identified in 39 loci from a GWAS of stroke,²⁴ and 40 genes in 64 loci from a GWAS of coronary artery disease²⁵ (Figure 5C). Thus, although the network was constructed from only 267 core proteins/genes, it covered substantial gene sets identified in GWAS and related studies.

Subsequently, we evaluated node connections and node centrality characteristics, such as proximity to other nodes (high for core nodes) and tendency to sub-clustering (low for core nodes) (Data File 6). mRNA expression levels in human megakaryocytes were determined for the network (Suppl. Figure 4 and 5A). For the novel nodes, it appeared that a substantial part of the corresponding genes were transcribed in megakaryocytes (Suppl. Figure 4A and 5B), and that most of these had 1-

4 connections with one or more modifying proteins in the network (Suppl. Figure 4B). Subsequently, we isolated the top 50 most connected novel proteins (Figure 5D), revealing some known proteins (*Cbl*, *Fyn*, *Lck*) but also proteins of novel pathways (*Anxa*, *Grm*, *Lpar*, *Nmur* family members).

Altered thrombus formation of mice deficient in newly identified genes

Taking into account the node characteristics, the PITH network was subsequently used to identify novel mouse genes with a possible role in arterial thrombosis. From the list of novel nodes with edges to modifying genes, we screened two groups of knockout mice for *in vitro* arterial thrombus formation (class III), which had not been evaluated yet in this way. One group came from the extensive Mouse Genetics breeding program of the Wellcome Sanger Institute in Cambridge (United Kingdom). These mice carried a homozygous deficiency in *Bnip2* (regulating cell death), *Dlg4* (membrane-associated guanylate kinase clustering signaling proteins), *Grm8* (Gi-coupled metabotropic glutamate receptor 8), *Ifnar1* (interferon receptor signaling via the JAK/STAT pathway) or *Vps13a* (involved in protein cycling through the trans-Golgi network) (Figure 6A). Mice deficient in two out of four genes with high mRNA expression in reference megakaryocytes (Figure 6B), *i.e.* *Ifnar1* and *Vps13a* but not *Bnip2* and *Dlg4*, gave a significant reduction in arterial thrombus formation (score -2). These findings are corroborated by recent papers showing that interferon I (ligand of *Ifnar1* transcript) regulates platelet count and function;²⁶ and that gene defects in human *VPS13A* are associated with chorea-acanthocytosis, where patients carry platelets with impaired granule secretion.²⁷ In accordance with low mRNA expression in reference megakaryocytes, *Grm8* deficiency did not affect thrombus formation (score 0).

The second group was provided by breeding programs of the Institute for Cardiovascular Prevention in Munich (Germany). This included animals with a homozygous deficiency in *Apoe* (apolipoprotein E, controlling the catabolism of lipoprotein triglycerides; affecting thrombosis *in vivo*, but not yet evaluated in class III), *Fpr2* (Gi protein-coupled formyl peptide receptor 2), or *Anxa1* (annexin A1, FPR2 ligand) (Figure 6C). These genes have been implicated in arteriosclerosis, and appear with multiple edges in the PITH network. Transcripts are expressed at medium to high levels in the liver,²⁸ but only *Anxa1* and *Apoe* transcripts are detectable at low levels in megakaryocytes. We found that deficiencies in *Apoe* and *Fpr2*, but not *Anxa1*, positively modified thrombus formation (*Apoe*^{-/-}, score +1 and *Fpr2*^{-/-} score +2) (Figure 6D). This implies that the prothrombotic role of FPR2 is independent of its proposed ligand ANX1. It appeared that 4 from the 8 novel genes with a predicted contribution to arterial thrombus formation, showed a phenotype in thrombus formation (*Ifnar1*, *Vps13a*, *Apoe*, *Fpr2*).

Discussion

Formal meta-analyses were performed to compare studies investigating consequences of genetic deficiency for experimental arterial thrombosis. The analyses were greatly impaired by high heterogeneity, as a consequence of small sample size (typically $n=6-12$) and differences in experimental set-up. To overcome these limitations, we developed an alternative synthesis approach, in which mouse studies of arterial thrombosis, thromboembolism, *in vitro* thrombus formation or bleeding were scaled, regardless of the thrombosis model and output parameters, *i.e.* features that greatly differ from laboratory to laboratory.¹⁰

Using a uniform normalization or scoring approach, we compared in total 1514 individual studies, investigating deficiencies in 431 mouse genes. Statistical analysis to compare 3-point and 5-point scores for different modes of thrombus induction, vascular beds and outcome parameters underlined the overall usefulness of a universal normalization procedure. It however also revealed subtle differences between established collagen-dependent models (*i.e.*, FeCl₃ or ligation/compression injury) and thrombosis models that were less collagen-dependent (laser or photochemical injury). This is in agreement with papers, indicating that the laser model is more dependent on tissue factor activity and/or mild endothelial damage, rather than collagen exposure, although this may depend on the severity of vascular trauma.²⁹⁻³¹ Regression analysis pointed to lower significance when comparing high vs. low collagen-dependent models.

Based on the statistical analysis of the collated data, it can be recommended for future thrombosis studies in mice to combine the results of the most commonly employed models (FeCl₃, ligation and laser injury of the carotid artery) in combination with multiple outcome measurements (*i.e.* not only time-to-occlusion). Taken together, the overall agreement in scoring scales – across main experimental variables - indicates that, in general, the effect of gene modification is larger than the variation caused by differences in methodology or measurement. In a next step, we accumulated the study scores per gene (treated as interval variables to allow statistical comparison) to calculate the consistency parameter CP as a measure of both the similarity and the number of evaluated studies.

This approach provided a valuable list of 60 consistently studied mouse genes ($n \geq 3$, $CP > 2.30$), which in majority encode coagulation, platelet membrane or signaling proteins contributing to thrombosis and/or hemostasis (Table 2). Together with mouse

models of human disease (*e.g.*, *Ano6*, *F8*, *Itgb3*, *Nbeal2*, *Vwf*), this list also contains many unexpected genes, where the relation to human disease still needs to be explored. For these 60 mouse genes/proteins, an overall high homology was present with the human orthologues (Suppl. Table 7). Given that only few drug targets are currently used for thrombosis treatment, this synthesis approach reveals several candidate proteins with a possible role in arterial thrombosis without bleeding. These include proteins that modulate functions of platelets, lipids, coagulation or fibrinolysis, as well as the vasculature.

In addition, our list contains only a few thrombosis-suppressive genes (*e.g.*, encoding for anticoagulant, fibrinolytic or vascular proteins). For several of these, in humans, deficiency is linked to an increased risk of (arterial) thrombosis (protein C, S, antithrombin). It will be important now to also investigate the thrombosis risk in humans for the other mouse genes with positive thrombosis scaling. On the other hand human genetics can also be less straightforward, as exemplified by the observation that a mutation of the *F5* (factor V) gene linked to altered binding of anticoagulant factors leads to a bleeding disorder,³² while the factor V Leiden allele of *F5* increases the risk of thrombosis.

For a larger set of 275 modifying mouse genes, information ($n \geq 1$, $CP \geq 1$) was present regarding a positive or negative role in arterial thrombosis (Data File 3). This synthesis approach thus may serve as an alternative for meta-analyses on mouse studies outside the field of thrombosis and hemostasis. Our synthesis approach also indicates that, for genes implicated in platelet function, measurement of thrombus formation using flow chambers *in vitro* can serve as a proxy test for assessment of (collagen-dependent) thrombus formation *in vivo*. Also, this supports implementation of

the 3Rs by: (i) refining *in vitro* procedures limiting the need for *in vivo* experiments; (ii) reducing numbers of animals, given the relatively small blood volumes needed for *in vitro* tests, and (iii) ultimately replacement of animal by human blood.

The PITH network revealed a wealth of candidate proteins and pathways possibly regulating arterial thrombus formation. Guided by node and centrality characteristics of the network, we could identify 4 novel mouse genes with a role in thrombus formation. Linking the network to large human databases of genetics of hemostasis and arterial thrombosis (Data File 6), mouse-human homology (Data File 4) and on-line Mendelian inheritance in man (OMIM) information (Suppl. Table 6) confirms its translational relevance. Hence, the PITH network can be used for setting priors when analyzing whole exome genome sequencing efforts for patients with rare inherited bleeding, thrombotic, or platelet disorders of unknown molecular etiology. It must be noted though that not all genes included in the PITH network are expressed in megakaryocytes and platelets, that functional redundancy can exist between protein isoforms, and that such redundancy can be different across species. Hence, single gene or protein deficiencies may not necessarily cause a thrombotic or hemorrhagic phenotype.

The present synthesis approach has also limitations. One restriction is the small number of mostly heterogeneous, low-powered studies per gene. The present synthesis approach aimed to integrate heterogeneous studies. Correlation analysis indicated consistency between the scores of groups and classes, indicating that the grouping and synthesis approach is justified. Another limitation is that the compiled mouse data include a relatively large set of genes that in man are linked to known inherited bleeding disorders, whereas genes with a role in the vascular component of thrombotic disorders

are underrepresented. A limitation of the collagen-based *in vitro* measurements of thrombus formation is that anti/pro-thrombotic changes due to altered coagulation, fibrinolysis or vascular dysfunction are not easily picked up.

In summary, this paper demonstrates that a novel synthesis approach based on scaling of distinct parameters of thrombus formation can integrate the effects of multiple small-size mouse studies to identify: (i) key genes and pathways of thrombotic processes in humans, and (ii) new molecular targets for antithrombotic therapy.

Acknowledgements

SdW, JMC and JWH have received funding from the Cardiovascular Center Maastricht, ZonMW (MKMD 114021004), the Interreg V Euregio Meuse-Rhine program (Poly-Valve), and the Netherlands Organization for Scientific Research (NWO Vidi 91716421 to JMC). Research in the Ouwehand laboratory was supported by program grants from the National Institute for Health Research to MK, SM and WHO and the British Heart Foundation under numbers RP-PG-0310-1002 and RG/09/12/28096; the laboratory also received funding from the NHS Blood and Transplant. MK was supported by Marie Curie funding from the NETSIM FP7 program, funded by the European Commission. OS received funding from the German Research Foundation (SO876/6-1, SFB914 B08, SFB1123 A06 & B05) and NWO (91712303). SJ was supported by the National Human Genome Research Institute at the National Institutes of Health (U41 HG003751).

Authors' contribution

CCB, SM and SMdW performed experiments, analyzed and interpreted data and wrote the paper; MAF and JMC analyzed and interpreted data and revised the manuscript; DJA, JWA, RRS, OS, CW and JKW provided essential tools and revised the paper; SJ, LG, MK, NJM and FS analyzed data; MHP interpreted data and revised the manuscript; WHO and JWH designed research, analyzed and interpreted data and wrote the paper.

Disclosure of conflicts of interests

The authors declare that they have no competing interests.

Corresponding authors:

Johan W. M. Heemskerk, Department of Biochemistry, CARIM, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Phone:31-43-3881671; Fax: 31-43-3884159; E-mail: jwm.heemskerk@maastrichtuniversity.nl

Willem H. Ouwehand, Department of Haematology, University of Cambridge & Wellcome Sanger Institute and NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, CB2 0PT United Kingdom. Phone: +44 (0)1223 58 8037/8018; E-mail: who1000@cam.ac.uk

References

1. World Health Organization. Factsheet Cardiovascular diseases *Factsheet No: 317*. 2013;<http://www.who.int/mediacentre/factsheets/fs317/en/>.
2. Mackman N. Triggers, targets and treatments for thrombosis. *Nature*. 2008;451(7181):914-8.
3. Jackson SP. Arterial thrombosis: insidious, unpredictable and deadly. *Nat Med*. 2011;17(11):1423-36.
4. Swieringa F, Kuijpers MJ, Heemskerk JW, van der Meijden PE. Targeting platelet receptor function in thrombus formation: the risk of bleeding. *Blood Rev*. 2014;28(1):9-21.
5. Westrick RJ, Ginsburg D. Modifier genes for disorders of thrombosis and hemostasis. *J Thromb Haemost*. 2009;7 Suppl 1:132-5.
6. Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. *J Thromb Haemost*. 2011;9 (Suppl. 1):92-104.
7. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. *Br J Haematol*. 2009;147(4):415-30.
8. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. *N Engl J Med*. 2011;364(18):1746-60.

9. Nieswandt B, Varga-Szabo D, Elvers M. Integrins in platelet activation. *J Thromb Haemost.* 2009;7 Suppl 1:206-9.
10. Denis CV, Dubois C, Brass LF, Heemskerk JW, Lenting PJ. Towards standardization of in vivo thrombosis studies in mice. *J Thromb Haemost.* 2011;9(8):1641-4.
11. Zwaginga JJ, Sakariassen KS, Nash G, King M, Heemskerk JW, Frojmovic M, et al. Flow based assays for global assessment of haemostasis. Part 2: current methods and considerations for the future. *J Thromb Haemost.* 2006;4(12):2716-7.
12. Emerson M. Refinement, reduction and replacement approaches to in vivo cardiovascular research. *Br J Pharmacol.* 2010;161(4):749-54.
13. De Witt SM, Swieringa F, Cavill R, Lamers MM, van Kruchten R, Mastenbroek T, et al. Identification of platelet function defects by multi-parameter assessment of thrombus formation. *Nat Commun.* 2014;5:4257.
14. Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, et al. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. *Thromb Haemost.* 2013;109(1):102-11.
15. Flamm MH, Colace TV, Chatterjee MS, Jing H, Zhou S, Jaeger D, et al. Multiscale prediction of patient-specific platelet function under flow. *Blood.* 2012;120(1):190-8.
16. Neeves KB, Onasoga AA, Hansen RR, Lilly JJ, Venckunaite D, Sumner MB, et al. Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays. *Plos One.* 2013;8(1):e54680.
17. Li R, Diamond SL. Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay. *Thromb Res.* 2014;133(2):203-10.
18. Schroll JB, Moustgaard R, Gotzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. *BMC Med Res Methodol.* 2011;11:22.
19. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. *J Thromb Haemost.* 2011;9 (Suppl. 1):76-91.
20. Jupe S, Akkerman JW, Soranzo N, Ouwehand WH. Reactome: a curated knowledgebase of biological pathways: megakaryocytes and platelets. *J Thromb Haemost* 2012;10(11):2399-402.
21. Thrombogenomics. <http://thrombo.cambridgednadiagnosis.org.uk/>. 2018.

22. Gieger C, Radhakrishnan A, Cvejic A, Tang W, Porcu E, et al. New gene functions in megakaryopoiesis and platelet formation. *Nature*. 2011;480(7376):201-8.
23. Petersen R, Lambourne JJ, Javierre BM, Grassi L, Kreuzhuber R, Ruklisa D, et al. Platelet function is modified by common sequence variation in megakaryocyte super enhancer. *Nat Commun*. 2017;8:16058.
24. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet*. 2018;50(4):524-37.
25. Van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circ Res*. 2018;122(3):433-43.
26. Rivadeneyra L, Pozner RG, Meiss R, Fondevila C, Gómez RM, Schattner M. Poly (I:C) downregulates platelet production and function through type I interferon. *Thromb Haemost*. 2015;114(5):982-93.
27. Schmidt EM, Schmid E, Münzer P, Hermann A, Eyrich AK, Russo A, et al. Chorein sensitivity of cytoskeletal organization and degranulation of platelets. *FASEB J*. 2013;27(7):2799-806.
28. GTEx Consortium, Laboratory DACCL, Fund NC, NIH/NC, NIH/NHGRI, NIH/NIMH, et al. Genetic effects on gene expression across human tissues. *Nature*. 2017;550(7675):204-13.
29. Eckly A, Hechler B, Freund M, Zerr M, Cazenave JP, Lanza F, et al. Mechanisms underlying FeCl₃-induced arterial thrombosis. *J Thromb Haemost*. 2011;9(4):779-89.
30. Mangin P, Yap CL, Nonne C, Sturgeon SA, Goncalves I, Yuan Y, et al. Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcR γ deficiency. *Blood*. 2006;107(11):4346-53.
31. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. *J Clin Invest*. 2007;117(4):953-60.
32. Vincent LM, Tran S, Livaja R, Benseid TA, Milewicz DM, Dahlbäck B. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPI α . *J Clin Invest*. 2013;123(9):3777-87.

33. Chen L, Kostadima M, Martens JH, Canu G, Garcia SP, Turro E, et al. Transcriptional diversity during lineage commitment of human blood progenitors. *Science*. 2014;345(6204):1251033.

Table 1. Correlations with scores per study in class I (*in vivo* thrombus formation) or class III (*in vitro* thrombus formation) for different vascular beds and different triggers.

Indicated are correlations across genes for similar genetically modified mice, used for studies in multiple classes, when scored on 3-point or 5-point scales. N refers to number of comparisons (genes) made. Comparison for indicated groups (injury modes, in *italic*) are indicated relative to carotid models (groups 1-4), FeCl₃ injury models (groups 1, 6, 9) or *in vitro* studies (group 30).

	Groups	N	3-point		5-point	
			<i>Kendall's τ</i>	<i>P-value</i>	<i>Kendall's τ</i>	<i>P-value</i>
Compared to carotis	<i>(1-4)</i>					
Mesentery	<i>6-8</i>	53	0.80	<0.001	0.53	<0.001
Cremaster	<i>9-11</i>	27	0.89	<0.001	0.66	<0.001
Compared to FeCl₃	<i>(1,6,9)</i>					
Laser	<i>8,11</i>	38	0.78	<0.001	0.50	0.001
Photochemical	<i>2,7,10</i>	27	0.67	<0.001	0.55	0.001
Ligation & compression	<i>3,5</i>	23	0.59	0.003	0.52	0.005
Compared to class III	<i>(30)</i>					
Carotis	<i>1-4</i>	77	0.57	<0.001	0.49	<0.001
Mesentery	<i>6-8</i>	65	0.77	<0.001	0.65	<0.001
Cremaster	<i>9-11</i>	35	0.80	<0.001	0.64	<0.001
FeCl ₃	<i>1,6,9,</i>	99	0.67	<0.001	0.62	<0.001
Laser	<i>8,11</i>	36	0.86	<0.001	0.56	0.001
Photochemical	<i>2,7,10</i>	15	0.26	0.325	0.46	0.056
Ligation & compression	<i>3,5</i>	24	0.87	<0.001	0.70	<0.001
Collagen/epinephrine	<i>20</i>	14	0.71	0.006	0.25	0.286

Table 2. Mouse and orthologous human genes with consistent contribution to arterial thrombosis with(out) altered bleeding. Mouse genes are listed with $n \geq 3$ scaled studies (5-point) and CP values of >2.30 ($P < 0.05$). Phenotype classification was according to reported changes regarding plasma, platelet or vascular phenotypes. Bold: mouse deficiency resulting in a highly prolonged bleeding (class IV, score -2). Underlined: human orthologues targeted in current clinical practice or trials.

Altered phenotype	Mouse deficiency	Human orthologue
<i>Antithrombotic, no prolonged bleeding</i>		
Plasma coagulation	<i>F11, F12</i>	<u><i>F11, F12</i></u>
Plasma fibrinolysis	<i>Serpine1</i>	<u><i>SERPINE1</i></u>
Platelet membrane	<i>Dusp3, Gp6, Itga6, P2rx1, Selp</i>	<u><i>DUSP3, GP6, ITGA6, P2RX1, SELP</i></u>
Platelet signaling	<i>Csnk2b, Pik3c3, Pik3cg, Pld1, Ppia, Prkca, Rhog, S100a9, Sgk1</i>	<u><i>CSNK2B, PIK3C3, PIK3CG, PLD1, PPIA, PRKCA, RHOG, S100A9, SGK1</i></u>
<i>Antithrombotic, prolonged bleeding</i>		
Coagulation	<i>F2, F8, F9, Klkb1, Vwf</i>	<u><i>F2, F8, F9, KLKB1, VWF</i></u> ,
Platelets		
membrane proteins	<i>Ano6, Clec1b, F2rl3, Fcer1g, Fermt3, Gna13, Gnaq, Gp1ba, GP1bb, Itga2, Itgb3, Mertk, Orai1, P2ry1, P2ry12, Pdia3, Pdia4, Ptpnj, Stim1, Trpm7, Tspan32</i>	<u><i>ANO6, CLEC1B, F2RL3, FCER1G, FERMT3, GNA13, GNAQ, GPIBA, GPIBB, ITGA2, ITGB3, MERTK, ORAI1, P2RY1, P2RY12, PDIA3, PDIA4, PTPRJ, STIM1, TRPM7, TSPAN32</i></u>
signaling	<i>Csk, Map3k5, Mapk8, Mapk14, Pdpk1, Pik3cb, Plcg2, Rac1, Rasgrp2, Tln1</i>	<u><i>CSK, MAP3K5, MAPK8, MAPK14, PDPK1, PIK3CB, PLCG2, RAC1, RASGRP2, TLN1</i></u>
secretion/activation	<i>Nbeal2, Kcnip3, Mmp2</i>	<u><i>NBEAL2, KCNIP3, MMP2</i></u>
Vessel wall	<i>Bambi, Bdkrb2, Mfap2</i>	<u><i>BAMBI, BDKRB2, MFAP2</i></u>
<i>Not antithrombotic, prolonged bleeding</i>		
Vessel wall	<i>Ceacam1/2</i>	<u><i>CEACAM1</i></u>

Figure Legends

Figure 1. Flowchart for scaling of parameters of arterial thrombosis and thromboembolism. Scored were studies of *in vivo* arterial thrombus formation (class I), thromboembolism (class II), and *in vitro* thrombus formation (class III) for mice with a genetic modification (GM) or pharmacological treatment, in comparison to wild type (WT) or the control condition. Indicated are scaling rules (scores) for the various output parameters on 3- and 5-point scales (values for WT set at 100%). For detailed description of groups and scoring procedures, see Suppl. Table 2.

Figure 2. Meta-analysis on contribution of *Cd36*, *Clec1b*, *F12*, *Fcer1g*, *GP6* or *Vwf* mouse genes to prolongation of FeCl₃-induced arterial thrombosis. Conventional meta-analysis assuming a standard random effects model, to compare effects of genetic deficiency in *Cd36*, *Clec1b*, *F12*, *Fcer1g*, *Gp6* or *Vwf* on prolongation time of arterial thrombus formation upon FeCl₃ injury. Given per gene are: standardized mean difference with 95% confidence interval (CI), test for overall effect (Z), and heterogeneity index (I²). See for details Data File 2.

Figure 3. Score distribution patterns of studies and mouse genes with increased or decreased thrombosis tendency or bleeding. Indicated are score distributions per class of numbers of mouse genes (A) or numbers of studies (B). Classes I-III refer to arterial thrombosis *in vivo*, systemic thromboembolism, and thrombus formation *in vitro*, respectively; class IV refers to tail bleeding times. In all cases scoring was at 5-point scale. Studies using mice with non-comparable genetics (e.g. gain-of-function mutations) were not included. C, Numbers of mouse genes with altered scores in classes I-III (5-point scale), in combination with prolonged (-2/-1), unchanged (0) or shortened (+1/+2) tail bleeding time (class IV).

Figure 4. Consistency analysis for the most frequently studied genes on effects on arterial thrombosis. **A**, Summation of scores per study for 35 indicated genes in classes I-III with $n \geq 6$. Data obtained from 312 studies (65% collagen-dependent models; 15% laser models, 7% photochemical injury). **B**, Mean scores per gene with 95% confidence intervals (95% CI). **C**, Calculated consistency parameter (CP) per gene [$1 - \log(P)$]. Note that a CP value >2.30 corresponds to a $P < 0.05$, and to 95% CI values not including zero.

Figure 5. Network of protein interactions in thrombosis and hemostasis (PITH). Network built in Cytoscape for 275 bait proteins, corresponding to mouse genes with modifying effect on arterial thrombosis of hemostasis. The final network has 267 core genes (bait nodes), 2679 new nodes, connected by 19721 interactions (edges). Of the edges, 15419 are derived from Reactome, 4299 from Intact, and 3 from manual assignment. Size of nodes is set as 1 per default, or as CP value. **A**, Network visualization with color-coded bait nodes: proteins modifying thrombosis (blue) or thrombosis + bleeding (red). Names are listed of 40 mouse genes with highest CP values. **B**, Network visualization with color-coded proteins linked to rare Mendelian disorders of human platelet or coagulant function (green, $n=54$); proteins linked to high association genes in GWAS of platelet count and volume (orange, $n=21$). **C**, Network visualization with additional purple-coded proteins linked to a recent GWAS of stroke ($n=11$) and coronary artery disease ($n=40$). **D**, Network visualization emphasizing 50 novel nodes with largest number of edges (≥ 25 , yellow). Attribute lists are given in Data File 6. The full network, containing gene expression levels in human megakaryocytes³³ and other annotation features, is available in Cytoscape format upon request. For enlarged panels, see Suppl. Figure 3.

Figure 6. Role of eight novel mouse genes in arterial thrombus formation, based on PITH network. Mice with homozygous deficiency in indicated genes were tested for arterial thrombus formation (class III). Data represent surface area coverage (SAC) of platelet thrombi on collagen. **A-B**, Testing of 5 genes/proteins selected from the PITH network with suspected thrombosis phenotype. Mean \pm SE ($n=6-17$), $**P < 0.01$. **C-D**, Testing of 3 genes/proteins identified from PITH with suspected gain-of-function defect

related to atherothrombosis. Mean \pm SE ($n=6-18$), $**P<0.01$. **B, D**, Connecting edges in PITH network, and relative mRNA expression in human megakaryocytes (log2 scale).

Figure 1





Figure 2

Std. Mean Difference
IV, Random, 95% CI


Cd36

Total (95% CI): 1.87 [-0.01, 3.76]
Test for overall effect: $Z = 1.95$ ($P = 0.05$)
Heterogeneity: $I^2 = 86\%$




Clec1b

Total (95% CI): 3.31 [-0.44, 7.05]
Test for overall effect: $Z = 1.73$ ($P = 0.08$)
Heterogeneity: $I^2 = 95\%$




F12

Total (95% CI): 4.36 [1.57, 7.68]
Test for overall effect: $Z = 2.97$ ($P = 0.003$)
Heterogeneity: $I^2 = 88\%$




Fcer1g

Total (95% CI): 0.67 [-0.05, 1.27]
Test for overall effect: $Z = 1.80$ ($P = 0.07$)
Heterogeneity: $I^2 = 0\%$



Gp6

Total (95% CI): 1.16 [0.37, 1.96]
Test for overall effect: $Z = 2.87$ ($P = 0.003$)
Heterogeneity: $I^2 = 73\%$



Vwf

Total (95% CI): 6.47 [2.70, 10.23]
Test for overall effect: $Z = 3.37$ ($P = 0.0008$)
Heterogeneity: $I^2 = 77\%$







Figure 3




Figure 4**A****B****C**







Figure 5

Figure 6**A****B**

	Bnip2	Dlg4	Grm8	Ifnar1	Vps13a
Connectors	2	8	25	2	2
MGK mRNA	6.68	3.43	0.04	2.50	4.55

C**D**

	Anxa1	Apoe	Fpr2
Connectors	31	137	27
MGK mRNA	0.64	0.84	0.06



blood[®]

Prepublished online October 1, 2018;
doi:10.1182/blood-2018-02-831982

A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding

Constance C. F. M. J. Baaten, Stuart Meacham, Susanne M. de Witt, Marion A. H. Feijge, David J. Adams, Jan-Willem N. Akkerman, Judith M. E. M. Cosemans, Luigi Grassi, Steve Jupe, Myrto Kostadima, Nadine J. A. Mattheij, Martin H. Prins, Ramiro Ramirez-Solis, Oliver Soehnlein, Frauke Swieringa, Christian Weber, Jacqueline K. White, Willem H. Ouweland and Johan W. M. Heemskerk

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.